1. Scrip
  2. >>Business

Scrip M&A Podcast: Assessing The Biopharma Deals Environment At Midyear

 
• By Joseph Haas, Kevin Grogan, and Mandy Jackson

With the first half of 2024 in the books, Scrip’s Joseph Haas, Mandy Jackson and Kevin Grogan discuss the dealmaking environment at the year’s midpoint and expectations for the second half.

Midyear M&A podcast
Scrip editors look ahead to biopharma dealmaking in the second half of 2024 • Source: Shutterstock

The midyear deal results are in for biopharmaceutical sector, with both merger-and-acquisition and alliance activity up compared to 2023 but with valuations coming in somewhat lower. Scrip editors Joseph Haas, Mandy Jackson and Kevin Grogan overview M&A and alliance activity seen during the first six months of 2024 and project what to expect during the year’s second half.

Haas sums up midyear prognostications from EY and PwC, outlines a recent talk he had with EY global life sciences deals leader Subin Baral, and also overviews his assessment of dealmaking so far this year in the biopharma sector

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives

 
• By Mandy Jackson

Restructuring Edition: Unity unveiled more Phase IIb data for lead asset UBX1325 along with plans to shed its workforce while seeking a partner for it and other drugs. Also, Ono is consolidating US employees at one site, Entrada is cutting its workforce by 20% and other recent strategic shifts.

Pharma Predicts Modest Impact From Tariffs, But It Depends On What Comes Next

 
• By Jessica Merrill

Drugmakers aren’t expecting a big financial hit from tariffs for now, but a report commissioned by PhRMA suggests the cost of pharma-sector tariffs could be steep.